GPT and venous thromboembolism: Safety concerns in other indication include serious infections (e.g., latent tuberculosis, herpes zoster), laboratory abnormalities (lymphopenia, neutropenia, anemia, elevated in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and lipids), as well as label-level signals for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) (36–38).